pomalidomide has been researched along with olaparib in 2 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | pomalidomide (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Chen, X; Dong, X; He, Q; Hong, J; Jiang, L; Li, K; Niu, T; Yang, B; Zhou, Z; Zhu, CL | 1 |
| Chung, M; Doctor, ZM; Donovan, KA; Eleuteri, NA; Fischer, ES; Gray, NS; Li, Z; Mills, CE; Nowak, RP; Olson, CM; Pinch, BJ; Scott, DA; Sorger, PK | 1 |
2 other study(ies) available for pomalidomide and olaparib
| Article | Year |
|---|---|
Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Topics: CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteolysis; Structure-Activity Relationship | 2022 |
Development and Characterization of a Wee1 Kinase Degrader.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; Drug Development; Female; Humans; Molecular Structure; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteolysis; Pyrazoles; Pyrimidinones; Thalidomide | 2020 |